Published in Cancer on July 15, 2010
Breast Cancer Survivorship & Work-Related Cognitive Limitation (BCSurvivorship) | NCT02303145
Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. J Clin Oncol (2015) 2.93
Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol (2012) 2.33
Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol (2012) 1.99
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol (2013) 1.62
Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol (2012) 1.49
Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer? Menopause (2013) 1.46
Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun (2012) 1.40
An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol (2011) 1.32
Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry (2014) 1.30
Altered small-world properties of gray matter networks in breast cancer. BMC Neurol (2012) 1.19
Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer (2013) 1.16
Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav Brain Res (2011) 1.16
Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis (2012) 1.14
Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors. JAMA Oncol (2016) 1.13
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin (2014) 1.12
Brain vulnerability to chemotherapy toxicities. Psychooncology (2012) 1.11
Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci U S A (2013) 1.09
Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer (2011) 1.07
Oxidative stress and neurodegenerative disorders. Int J Mol Sci (2013) 1.04
Cognitive function and fatigue after diagnosis of colorectal cancer. Ann Oncol (2014) 1.02
A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front Oncol (2015) 1.01
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol (2014) 1.00
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know? Semin Oncol (2013) 0.99
The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav (2013) 0.95
Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer (2011) 0.95
Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine (2015) 0.94
The utility of parent report in the assessment of working memory among childhood brain tumor survivors. J Int Neuropsychol Soc (2013) 0.92
Stem cell transplantation reverses chemotherapy-induced cognitive dysfunction. Cancer Res (2015) 0.92
Multivariate pattern analysis of FMRI in breast cancer survivors and healthy women. J Int Neuropsychol Soc (2013) 0.92
Patterns of change in cognitive function with anastrozole therapy. Cancer (2015) 0.91
Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Res (2015) 0.90
Opening up the window into "chemobrain": a neuroimaging review. Sensors (Basel) (2013) 0.89
Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer (2014) 0.88
A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci (2013) 0.88
Systemic chemotherapy decreases brain glucose metabolism. Ann Clin Transl Neurol (2014) 0.88
Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer (2013) 0.87
Default mode network as a potential biomarker of chemotherapy-related brain injury. Neurobiol Aging (2014) 0.87
Cognitive features 10 or more years after successful breast cancer survival: comparisons across types of cancer interventions. Psychooncology (2012) 0.86
Apolipoprotein E genotype and cognitive function in postmenopausal women with early-stage breast cancer. Oncol Nurs Forum (2014) 0.85
The chemotherapeutic agent paclitaxel selectively impairs learning while sparing source memory and spatial memory. Behav Brain Res (2016) 0.84
Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiol Aging (2015) 0.83
A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus (2014) 0.83
Long-term Toxicity of Cancer Treatment in Older Patients. Clin Geriatr Med (2015) 0.83
Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer (2010) 0.82
Post-treatment Neurocognition and Psychosocial Care Among Breast Cancer Survivors. Am J Prev Med (2015) 0.82
Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Breast Cancer Res Treat (2014) 0.82
Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: findings from a prospective cohort study. Med Care (2012) 0.82
Opportunities for public health communication, intervention, and future research on breast cancer in younger women. J Womens Health (Larchmt) (2013) 0.81
Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. ScientificWorldJournal (2012) 0.81
Psychometric analysis of the Patient Assessment of Own Functioning Inventory in women with breast cancer. J Nurs Meas (2013) 0.80
Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav (2013) 0.80
A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv (2015) 0.79
Survivorship: cognitive function, version 1.2014. J Natl Compr Canc Netw (2014) 0.79
Doxorubicin attenuates serotonin-induced long-term synaptic facilitation by phosphorylation of p38 mitogen-activated protein kinase. J Neurosci (2014) 0.79
A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology (2013) 0.78
Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: a population-based prospective cohort. Oncologist (2011) 0.78
Memory and cancer: a review of the literature. Arch Psychiatr Nurs (2014) 0.78
Interventions to Alleviate Symptoms Related to Breast Cancer Treatments and Areas of Needed Research. J Cancer Sci Ther (2011) 0.78
The impact of cancer therapy on cognition in the elderly. Front Pharmacol (2013) 0.78
Selecting a comparison group for 5-year oral and pharyngeal cancer survivors: two methods. BMC Med Res Methodol (2012) 0.77
Preserved learning and memory following 5-fluorouracil and cyclophosphamide treatment in rats. Pharmacol Biochem Behav (2011) 0.77
An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer (2012) 0.77
Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Sci Rep (2016) 0.77
Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol (2016) 0.76
Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer (2016) 0.76
Effects of Exercise Interventions and Physical Activity Behavior on Cancer Related Cognitive Impairments: A Systematic Review. Biomed Res Int (2016) 0.76
Exploring the measurement properties of the Montreal Cognitive Assessment in a population of people with cancer. Support Care Cancer (2015) 0.76
Perceived cognitive function for breast cancer survivors: association of genetic and behaviorally related variables for inflammation. Support Care Cancer (2017) 0.75
Relationships among psychoneurological symptoms and levels of C-reactive protein over 2 years in women with early-stage breast cancer. Support Care Cancer (2016) 0.75
What You Do Not Know Could Hurt You: What Women Wish Their Doctors Had Told Them About Chemotherapy Side Effects on Memory and Response to Alcohol. Breast Cancer (Auckl) (2016) 0.75
The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res (2016) 0.75
Management of Potential Long-Term Toxicities in Breast Cancer Patients. Curr Breast Cancer Rep (2016) 0.75
Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study. Neuropsychiatr Dis Treat (2017) 0.75
Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. Brain Imaging Behav (2016) 0.75
Dysregulation of Microtubule Stability Impairs Morphofunctional Connectivity in Primary Neuronal Networks. Front Cell Neurosci (2017) 0.75
Effect of an Internet-based telehealth system on functional capacity and cognition in breast cancer survivors: a secondary analysis of a randomized controlled trial. Support Care Cancer (2017) 0.75
Altered intrinsic brain activity after chemotherapy in patients with gastric cancer: A preliminary study. Eur Radiol (2016) 0.75
Effects of compensatory cognitive training intervention for breast cancer patients undergoing chemotherapy: a pilot study. Support Care Cancer (2017) 0.75
A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 mice. Transl Psychiatry (2017) 0.75
Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatment. Support Care Cancer (2016) 0.75
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 9.90
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
Breast carcinoma in men: a population-based study. Cancer (2004) 4.88
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer (2004) 3.50
Breast cancer in men. Ann Intern Med (2002) 3.39
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst (2008) 3.17
Is breast cancer survival improving? Cancer (2004) 2.73
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (2003) 2.48
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol (2008) 2.42
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol (2008) 2.40
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol (2005) 2.39
Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery (2004) 2.38
Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat (2003) 2.26
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol (2005) 2.07
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer (2003) 2.01
'Chemobrain' in breast carcinoma?: a prologue. Cancer (2004) 1.98
Evolving novel anti-HER2 strategies. Lancet Oncol (2009) 1.90
Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol (2008) 1.88
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol (2012) 1.75
Trends for inflammatory breast cancer: is survival improving? Oncologist (2007) 1.70
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg (2006) 1.70
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. Int J Radiat Oncol Biol Phys (2003) 1.60
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol (2012) 1.59
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer (2007) 1.56
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer (2011) 1.53
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys (2002) 1.51
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.51
Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol (2002) 1.47
Neurocognitive function before and after surgery for insular gliomas. J Neurosurg (2011) 1.44
The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol (2003) 1.36
Update on the management of inflammatory breast cancer. Oncologist (2003) 1.36
Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev (2008) 1.35
Adjuvant systemic therapy for male breast carcinoma. Cancer (2005) 1.34
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol (2002) 1.33
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys (2008) 1.33
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol (2005) 1.33
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol (2007) 1.32
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer (2004) 1.30
Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer (2004) 1.29
Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation. Cancer (2008) 1.27
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol (2004) 1.25
Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys (2013) 1.24
Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst (2005) 1.23
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer (2004) 1.22
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol (2002) 1.20
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.20
Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer (2005) 1.19
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res (2010) 1.14
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer (2010) 1.11
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer (2004) 1.11
Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol (2006) 1.10
Efficacy of anastrozole in male breast cancer. Am J Clin Oncol (2002) 1.07
A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery (2007) 1.05
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg (2011) 1.05
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys (2003) 1.04
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg (2006) 1.03
Staging of breast cancer in the neoadjuvant setting. Cancer Res (2008) 1.03
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (2011) 1.02
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol (2011) 1.02
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol (2013) 1.02
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer (2011) 1.01
Does brain tumor histology influence cognitive function? Neuro Oncol (2003) 1.00
Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst (2004) 1.00
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer (2010) 1.00
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol (2002) 1.00
Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep (2005) 0.98
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res (2002) 0.98
Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol (2012) 0.98
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol (2004) 0.98
Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol (2009) 0.97
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer (2007) 0.97
Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol (2003) 0.96
A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer (2004) 0.96
Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci (2004) 0.95
Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol (2006) 0.95
Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer (2004) 0.94
Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer (2002) 0.94
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J (2002) 0.93
Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J (2007) 0.93
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer (2003) 0.92
Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract (2007) 0.92
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys (2002) 0.92
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res (2007) 0.91
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer (2006) 0.90